<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906399</url>
  </required_header>
  <id_info>
    <org_study_id>105MS301</org_study_id>
    <secondary_id>2008-006333-27</secondary_id>
    <nct_id>NCT00906399</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis</brief_title>
  <acronym>ADVANCE</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the efficacy of peginterferon beta-1a in
      reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis
      (RMS) at 1 year. The secondary objectives of this study are to determine whether
      peginterferon beta-1a, at 1 year when compared with placebo, is effective in reducing the
      total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance
      imaging (MRI) scans, reducing the proportion of participants who relapse, and slowing the
      progression of disability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a global multicenter, randomized, double-blind, parallel-group, placebo-controlled
      study. The treatment period is 96 weeks (2 years) in duration. Treatment Year 1 (Week 0 to
      Week 48) is referred to as the placebo-controlled treatment period of the study. At the
      beginning of Treatment Year 1, participants were randomized to receive placebo, peginterferon
      beta-1a 125 μg every 2 weeks, or peginterferon beta-1a 125 μg every 4 weeks. At the end of
      Treatment Year 1, participants in the placebo group were re-randomized to receive
      peginterferon beta-1a treatment so that during treatment Year 2 (Weeks 48 to Week 96) all
      participants received peginterferon beta-1a 125 μg every 2 or every 4 weeks. Per protocol,
      all primary and secondary endpoints pertain to Year 1 data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Relapse Rate (ARR) at 1 Year</measure>
    <time_frame>1 Year</time_frame>
    <description>A relapse is defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting for at least 24 hours, and accompanied by new objective neurologic findings. Only relapses confirmed by an independent neurology evaluation committee (INEC) are included in the analysis. Data after participants switched to alternative multiple sclerosis (MS) medications are excluded. Data were analyzed using negative binomial regression, adjusted for baseline Expanded Disability Status Scale (EDSS) score (&lt; 4 versus ≥ 4), baseline age (&lt; 40 versus ≥ 40 years), and baseline relapse rate (number of relapses in 3 years prior to study entry divided by 3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of New Or Newly Enlarging T2 Hyperintense Lesions at 1 Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans. Data observed after participants switched to alternative MS medications are excluded. Adjusted mean is based on negative binomial regression, adjusted for baseline number of T2 lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Relapsed at 1 Year</measure>
    <time_frame>Year 1</time_frame>
    <description>A relapse is defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting for at least 24 hours, and accompanied by new objective neurologic findings. Only relapses confirmed by INEC were included in the analysis. Estimated proportion of participants relapsed is based on the Kaplan-Meier product limit method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Proportion of Participants With Sustained Disability Progression at 1 Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Sustained disability progression is defined as: at least a 1.0 point increase on the EDSS from baseline EDSS ≥ 1.0 that is sustained for 12 weeks, or at least a 1.5 point increase on the EDSS from baseline EDSS = 0 that is sustained for 12 weeks. The EDSS measures the disability status of people with MS on a scale that ranges from 0 to 10. The range of main categories include 0 (normal neurologic examination), to 5 (ambulatory without aid or rest for 200 meters/disability severe enough to impair full daily activities), to 10 (death due to MS). Estimated proportion of participants with progression based on the Kaplan-Meier product limit method.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1516</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 or 4 weeks for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon Beta-1a Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon Beta-1a Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 96 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB017 (peginterferon beta-1a)</intervention_name>
    <description>Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.</description>
    <arm_group_label>Peginterferon Beta-1a Q4W</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Peginterferon Beta-1a Q2W</arm_group_label>
    <other_name>PEG IFN ß-1a</other_name>
    <other_name>PEGylated interferon beta-1a</other_name>
    <other_name>Plegridy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.</description>
    <arm_group_label>Peginterferon Beta-1a Q4W</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have a confirmed diagnosis of relapsing multiple sclerosis (RMS), as defined by
             McDonald criteria 1 through 4 (Polman, 2005)

          -  Must have an EDSS score between 0.0 and 5.0.

          -  Must have experienced at least 2 relapses that have been medically documented within
             the last 3 years with at least one occurring in the last 12 months

        Key Exclusion Criteria:

          -  Other chronic disease of immune system, malignancies, urologic, pulmonary,
             gastrointestinal disease

          -  Pregnant or nursing women

          -  Prior treatment with interferon could not exceed 4 weeks and subjects must have
             discontinued interferon treatment 6 months prior to Baseline

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ponte Vedra Beach</city>
        <state>Florida</state>
        <zip>32082 4040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607 6520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>'Sint-Truiden</city>
        <zip>3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava - Vitkovice</city>
        <zip>70200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>70300</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <zip>41529</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parnu</city>
        <zip>EE 80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <zip>EE 10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <zip>EE 51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice</city>
        <zip>6002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>141</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>14163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munchen</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prien</city>
        <zip>83209</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <zip>89079</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saket</city>
        <state>Delhi</state>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rajkot</city>
        <state>Gujarat</state>
        <zip>360001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indore</city>
        <state>Madhyr Pradesh</state>
        <zip>452018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nasik</city>
        <state>Maharashtra</state>
        <zip>422004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amritsar</city>
        <state>Punjab</state>
        <zip>143001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mangalore</city>
        <zip>575018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Navi Mumbai</city>
        <zip>400703</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nehru Nagar</city>
        <zip>110065</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 1005</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aquas Calientes</city>
        <zip>20127</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chihuahua</city>
        <zip>31203</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <zip>10700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico DF</city>
        <zip>03310</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey, Nuevo Leon</city>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tijuana, Baja California</city>
        <zip>22320</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <zip>4818CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 21</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Isidro</city>
        <zip>Lima 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80299</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40650</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40662</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40684</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Konskie</city>
        <zip>26200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10082</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plewiska</city>
        <zip>62064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>61853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70215</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warsawa</city>
        <zip>00851</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warsawa</city>
        <zip>02957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warsawa</city>
        <zip>04141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warsawa</city>
        <zip>04749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zabrze</city>
        <zip>41800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <zip>500123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>50098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Campulung</city>
        <zip>115100</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <zip>700656</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sibiu</city>
        <zip>550166</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaluga</city>
        <zip>248007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kursk</city>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>107150</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>119021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <zip>14008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Donetsk</city>
        <zip>83099</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>3110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>4107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <zip>26011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Simferopol</city>
        <zip>95017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ternopil</city>
        <zip>46027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.</citation>
    <PMID>24794721</PMID>
  </results_reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <results_first_submitted>July 28, 2014</results_first_submitted>
  <results_first_submitted_qc>September 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2014</results_first_posted>
  <disposition_first_submitted>June 17, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>June 17, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 20, 2014</disposition_first_posted>
  <last_update_submitted>September 15, 2014</last_update_submitted>
  <last_update_submitted_qc>September 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interferon</keyword>
  <keyword>injectable</keyword>
  <keyword>MS</keyword>
  <keyword>SC</keyword>
  <keyword>PEGylated</keyword>
  <keyword>Interferon beta-1a</keyword>
  <keyword>relapsing</keyword>
  <keyword>PEG</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>subcutaneous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Year 1: Placebo</title>
          <description>Placebo every 2 weeks for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>Year 1: Peginterferon Beta-1a Q4W</title>
          <description>125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 48 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
        </group>
        <group group_id="P3">
          <title>Year 1: Peginterferon Beta-1a Q2W</title>
          <description>125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 48 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Year 2: Placebo Followed by Peginterferon Beta-1a Q4W</title>
          <description>Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 4 weeks for 48 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
        </group>
        <group group_id="P5">
          <title>Year 2: Placebo Followed by Peginterferon Beta-1a Q2W</title>
          <description>Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 weeks for 48 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Year 2: Peginterferon Beta-1a Q4W</title>
          <description>125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 48 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
        </group>
        <group group_id="P7">
          <title>Year 2: Peginterferon Beta-1a Q2W</title>
          <description>125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Year 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="501"/>
                <participants group_id="P3" count="515"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Year 1 Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="456"/>
                <participants group_id="P2" count="438"/>
                <participants group_id="P3" count="438"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="456"/>
                <participants group_id="P2" count="438"/>
                <participants group_id="P3" count="439">1 participant discontinued treatment before end of study period but remained to complete follow-up.</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized But Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Year 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="228"/>
                <participants group_id="P5" count="228"/>
                <participants group_id="P6" count="438"/>
                <participants group_id="P7" count="438"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Year 2 Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="200"/>
                <participants group_id="P5" count="196"/>
                <participants group_id="P6" count="391"/>
                <participants group_id="P7" count="411"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="198"/>
                <participants group_id="P5" count="193"/>
                <participants group_id="P6" count="391"/>
                <participants group_id="P7" count="409"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="35"/>
                <participants group_id="P6" count="47"/>
                <participants group_id="P7" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="27"/>
                <participants group_id="P7" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat population: participants who were randomized and received at least 1 dose of study treatment (peginterferon beta-1a or placebo).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo every 2 weeks for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>Peginterferon Beta-1a Q4W</title>
          <description>125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 48 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
        </group>
        <group group_id="B3">
          <title>Peginterferon Beta-1a Q2W</title>
          <description>125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 48 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="500"/>
            <count group_id="B2" value="500"/>
            <count group_id="B3" value="512"/>
            <count group_id="B4" value="1512"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="9.74"/>
                    <measurement group_id="B2" value="36.4" spread="9.87"/>
                    <measurement group_id="B3" value="36.9" spread="9.79"/>
                    <measurement group_id="B4" value="36.5" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="358"/>
                    <measurement group_id="B2" value="352"/>
                    <measurement group_id="B3" value="361"/>
                    <measurement group_id="B4" value="1071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded Disability Status Scale (EDSS)</title>
          <description>The EDSS measures the disability status of people with multiple sclerosis (MS) on a scale that ranges from 0 to 10. The range of main categories include 0 (normal neurologic exam), to 5 (ambulatory without aid or rest for 200 meters/disability severe enough to impair full daily activities), to 10 (death due to MS).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.44" spread="1.180"/>
                    <measurement group_id="B2" value="2.48" spread="1.244"/>
                    <measurement group_id="B3" value="2.47" spread="1.255"/>
                    <measurement group_id="B4" value="2.46" spread="1.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualized Relapse Rate (ARR) at 1 Year</title>
        <description>A relapse is defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting for at least 24 hours, and accompanied by new objective neurologic findings. Only relapses confirmed by an independent neurology evaluation committee (INEC) are included in the analysis. Data after participants switched to alternative multiple sclerosis (MS) medications are excluded. Data were analyzed using negative binomial regression, adjusted for baseline Expanded Disability Status Scale (EDSS) score (&lt; 4 versus ≥ 4), baseline age (&lt; 40 versus ≥ 40 years), and baseline relapse rate (number of relapses in 3 years prior to study entry divided by 3).</description>
        <time_frame>1 Year</time_frame>
        <population>Intent-to-treat (ITT) population: participants who were randomized and received at least 1 dose of study treatment (peginterferon beta-1a or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Year 1: Placebo</title>
            <description>Placebo every 2 weeks for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Year 1: Peginterferon Beta-1a Q4W</title>
            <description>125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 48 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
          </group>
          <group group_id="O3">
            <title>Year 1: Peginterferon Beta-1a Q2W</title>
            <description>125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate (ARR) at 1 Year</title>
          <description>A relapse is defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting for at least 24 hours, and accompanied by new objective neurologic findings. Only relapses confirmed by an independent neurology evaluation committee (INEC) are included in the analysis. Data after participants switched to alternative multiple sclerosis (MS) medications are excluded. Data were analyzed using negative binomial regression, adjusted for baseline Expanded Disability Status Scale (EDSS) score (&lt; 4 versus ≥ 4), baseline age (&lt; 40 versus ≥ 40 years), and baseline relapse rate (number of relapses in 3 years prior to study entry divided by 3).</description>
          <population>Intent-to-treat (ITT) population: participants who were randomized and received at least 1 dose of study treatment (peginterferon beta-1a or placebo).</population>
          <units>relapses per person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="512"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.397" lower_limit="0.328" upper_limit="0.481"/>
                    <measurement group_id="O2" value="0.288" lower_limit="0.234" upper_limit="0.355"/>
                    <measurement group_id="O3" value="0.256" lower_limit="0.206" upper_limit="0.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0114</p_value>
            <method>Negative Binomial Regression</method>
            <method_desc>Based on negative binomial regression, with adjustment for baseline EDSS (&lt; 4 versus ≥ 4), baseline relapse rate, age (&lt; 40 versus ≥ 40 years).</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.725</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.565</ci_lower_limit>
            <ci_upper_limit>0.930</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Negative Binomial Regression</method>
            <method_desc>Based on negative binomial regression, with adjustment for baseline EDSS (&lt; 4 versus ≥ 4), baseline relapse rate, age (&lt; 40 versus ≥ 40).</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.644</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.500</ci_lower_limit>
            <ci_upper_limit>0.831</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New Or Newly Enlarging T2 Hyperintense Lesions at 1 Year</title>
        <description>Number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans. Data observed after participants switched to alternative MS medications are excluded. Adjusted mean is based on negative binomial regression, adjusted for baseline number of T2 lesions.</description>
        <time_frame>1 Year</time_frame>
        <population>ITT population, with at least 1 post-baseline assessment. Missing data prior to alternative MS medications and visits after participants switched to alternative MS medications imputed based on previous visit data assuming the constant rate of lesion development or group mean at same visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Year 1: Placebo</title>
            <description>Placebo every 2 weeks for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Year 1: Peginterferon Beta-1a Q4W</title>
            <description>125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 48 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
          </group>
          <group group_id="O3">
            <title>Year 1: Peginterferon Beta-1a Q2W</title>
            <description>125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New Or Newly Enlarging T2 Hyperintense Lesions at 1 Year</title>
          <description>Number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans. Data observed after participants switched to alternative MS medications are excluded. Adjusted mean is based on negative binomial regression, adjusted for baseline number of T2 lesions.</description>
          <population>ITT population, with at least 1 post-baseline assessment. Missing data prior to alternative MS medications and visits after participants switched to alternative MS medications imputed based on previous visit data assuming the constant rate of lesion development or group mean at same visit.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="476"/>
                <count group_id="O2" value="462"/>
                <count group_id="O3" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="19.51" lower_limit="9.6" upper_limit="12.5"/>
                    <measurement group_id="O2" value="7.9" spread="15.84" lower_limit="6.9" upper_limit="9.0"/>
                    <measurement group_id="O3" value="3.6" spread="8.55" lower_limit="3.1" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Negative Binomial Regression</method>
            <method_desc>Lesion mean ratio (95% CI) and p-value based on negative binomial regression, adjusted for baseline number of T2 lesions.</method_desc>
            <param_type>Lesion Mean Ratio</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Negative Binomial Regression</method>
            <method_desc>Lesion mean ratio (95% CI) and p-value based on negative binomial regression, adjusted for baseline number of T2 lesions.</method_desc>
            <param_type>Lesion Mean Ratio</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Relapsed at 1 Year</title>
        <description>A relapse is defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting for at least 24 hours, and accompanied by new objective neurologic findings. Only relapses confirmed by INEC were included in the analysis. Estimated proportion of participants relapsed is based on the Kaplan-Meier product limit method.</description>
        <time_frame>Year 1</time_frame>
        <population>ITT population: participants who were randomized and received at least 1 dose of study treatment (peginterferon beta-1a or placebo). Participants who did not experience a relapse prior to switching to alternative MS medications or withdrew from study were censored at the time of switch/withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>Year 1: Placebo</title>
            <description>Placebo every 2 weeks for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Year 1: Peginterferon Beta-1a Q4W</title>
            <description>125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 48 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
          </group>
          <group group_id="O3">
            <title>Year 1: Peginterferon Beta-1a Q2W</title>
            <description>125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Relapsed at 1 Year</title>
          <description>A relapse is defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting for at least 24 hours, and accompanied by new objective neurologic findings. Only relapses confirmed by INEC were included in the analysis. Estimated proportion of participants relapsed is based on the Kaplan-Meier product limit method.</description>
          <population>ITT population: participants who were randomized and received at least 1 dose of study treatment (peginterferon beta-1a or placebo). Participants who did not experience a relapse prior to switching to alternative MS medications or withdrew from study were censored at the time of switch/withdrawal.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="512"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.291"/>
                    <measurement group_id="O2" value="0.222"/>
                    <measurement group_id="O3" value="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0200</p_value>
            <p_value_desc>Based on Cox proportion hazards model, adjusted for baseline EDSS (&lt; 4 versus ≥ 4), age (&lt;40 versus ≥ 40 years), baseline relapse rate, and baseline Gd enhancing lesions (presence versus absence).</p_value_desc>
            <method>Cox Proportion Hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Based on Cox proportion hazards model, adjusted for baseline EDSS (&lt; 4 versus ≥ 4), age (&lt;40 versus ≥ 40 years), baseline relapse rate, and baseline Gd enhancing lesions (presence versus absence).</p_value_desc>
            <method>Cox Proportion Hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Proportion of Participants With Sustained Disability Progression at 1 Year</title>
        <description>Sustained disability progression is defined as: at least a 1.0 point increase on the EDSS from baseline EDSS ≥ 1.0 that is sustained for 12 weeks, or at least a 1.5 point increase on the EDSS from baseline EDSS = 0 that is sustained for 12 weeks. The EDSS measures the disability status of people with MS on a scale that ranges from 0 to 10. The range of main categories include 0 (normal neurologic examination), to 5 (ambulatory without aid or rest for 200 meters/disability severe enough to impair full daily activities), to 10 (death due to MS). Estimated proportion of participants with progression based on the Kaplan-Meier product limit method.</description>
        <time_frame>1 Year</time_frame>
        <population>ITT population: participants who were randomized and received at least 1 dose of study treatment (peginterferon beta-1a or placebo). Participants were censored at the time of withdrawal/switch if they withdrew from study or switched to alternative MS medication without a progression.</population>
        <group_list>
          <group group_id="O1">
            <title>Year 1: Placebo</title>
            <description>Placebo every 2 weeks for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Year 1: Peginterferon Beta-1a Q4W</title>
            <description>125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 48 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
          </group>
          <group group_id="O3">
            <title>Year 1: Peginterferon Beta-1a Q2W</title>
            <description>125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Proportion of Participants With Sustained Disability Progression at 1 Year</title>
          <description>Sustained disability progression is defined as: at least a 1.0 point increase on the EDSS from baseline EDSS ≥ 1.0 that is sustained for 12 weeks, or at least a 1.5 point increase on the EDSS from baseline EDSS = 0 that is sustained for 12 weeks. The EDSS measures the disability status of people with MS on a scale that ranges from 0 to 10. The range of main categories include 0 (normal neurologic examination), to 5 (ambulatory without aid or rest for 200 meters/disability severe enough to impair full daily activities), to 10 (death due to MS). Estimated proportion of participants with progression based on the Kaplan-Meier product limit method.</description>
          <population>ITT population: participants who were randomized and received at least 1 dose of study treatment (peginterferon beta-1a or placebo). Participants were censored at the time of withdrawal/switch if they withdrew from study or switched to alternative MS medication without a progression.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="512"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.105"/>
                    <measurement group_id="O2" value="0.068"/>
                    <measurement group_id="O3" value="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0380</p_value>
            <p_value_desc>Based on Cox Proportional Hazards model, adjusted for baseline EDSS (&lt; 4 versus ≥ 4) and age (&lt; 40 versus ≥ 40 years).</p_value_desc>
            <method>Cox Proportion Hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0383</p_value>
            <p_value_desc>Based on Cox Proportional Hazards model, adjusted for baseline EDSS (&lt; 4 versus ≥ 4) and age (&lt; 40 versus ≥ 40 years).</p_value_desc>
            <method>Cox Proportion Hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening through Week 96 (treatment period), plus 4 weeks (±5 days) follow-up</time_frame>
      <desc>One participant, randomized to placebo-&gt;Q4W, received one wrong dosing kit during Year 1, and was mistakenly distributed with one Q2W kit, therefore receiving study drug in Weeks 20 and 22 instead of placebo. For Year 1 safety tables, this participant was grouped with Q2W, and for Year 2 safety tables, this participant was grouped with Q4W.</desc>
      <group_list>
        <group group_id="E1">
          <title>Year 1: Placebo</title>
          <description>Placebo every 2 weeks for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>Year 1: Peginterferon Beta-1a Q4W</title>
          <description>125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 48 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
        </group>
        <group group_id="E3">
          <title>Year 1: Peginterferon Beta-1a Q2W</title>
          <description>125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 48 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Year 2: Placebo Followed by Peginterferon Beta-1a Q4W</title>
          <description>Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 4 weeks for 48 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
        </group>
        <group group_id="E5">
          <title>Year 2: Placebo Followed by Peginterferon Beta-1a Q2W</title>
          <description>Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 weeks for 48 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Year 2: Peginterferon Beta-1a Q4W</title>
          <description>125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 48 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).</description>
        </group>
        <group group_id="E7">
          <title>Year 2: Peginterferon Beta-1a Q2W</title>
          <description>125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="67" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="39" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital Cystic Kidney Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Intestinal Strangulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Drug-Induced Liver Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hepatic Function Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hepatitis Toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Infected Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Bacterial Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cellulitis Gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Myometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Salpingo-Oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Typhoid Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Viral Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Viral Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Avulsion Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Craniocerebral Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Patellofemoral Pain Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Enthesopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Sacroilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Vulval Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cervix Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Lip And/Or Oral Cavity Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Neuritis Cranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Neuromyelitis Optica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Partial Seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Partial Seizures With Secondary Generalization</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Uhthoff's Phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Bulbar Palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Complex Partial Seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Extrapyramidal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Trigeminal Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Incomplete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Personality Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Conversion Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Micturition Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cervical Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Ectropion Of Cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Epididymal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pelvic Adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Uterine Cervical Erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Organising Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="378" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="466" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="472" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="190" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="206" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="373" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="367" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="282" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="315" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="119" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="135" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="211" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="212" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="234" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="238" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="95" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="106" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="199" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="192" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="218" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="227" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="138" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="136" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="52" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="41" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="45" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="40" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="47" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="47" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body Temperature Increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="60" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="58" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="33" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="31" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="225" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="64" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="122" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="126" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="95" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="63" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="513"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biogen Idec Study Medical Director</name_or_title>
      <organization>Biogen Idec</organization>
      <email>clinicaltrials@biogenidec.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

